Allogene Therapeutics’ Post

Could your patients be eligible for the KOMET-008 clinical trial aimed at evaluating ziftomenib, a menin inhibitor, with other existing standard-of-care treatments in relapsed or refractory acute myeloid leukemia? Hematologist-oncologist Harry Erba, MD, PhD, explains the different combinations KOMET-008 will evaluate and how it differs from KOMET-007. KOMET-008 is OPENING SOON. Learn more: https://lnkd.in/g37mAZZq

Over the last decades, outcomes in B-cell acute lymphoblastic leukemia (B-ALL) have improved enormously thanks to developments in treatment. However, drug resistance and relapse, particularly among adults patients, is still a big challenge. This issue of Haematologica reports on a new potential therapeutic target for B-ALL: the mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1). https://lnkd.in/d8t4pABj

Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia? Authors: Ramy Rahmé & Thorsten Braun I am happy to share with you our latest opinion article/review on the treatment of refractory/relapsed acute myeloid leukemia with intensive chemotherapy approaches. In particular, we focus on chemotherapeutic regimens incorporating the BCL2 inhibitor venetoclax. Available data are indeed scarce on this matter. Still, they show higher rates of complete remission than historical reports, bridging a substantial number of patients to allogeneic transplant with the potential of cure. Website:

📢 FDA Grant Accelerated Approval to CAR-T Breyanzi in 3L r/r Follicular Lymphoma (Juno Therapeutics, Inc.) ➤ AA based on ORR from Phase 2, single-arm TRANSCEND-FL (NCT04245839) in adults with relapsed or refractory FL after two or more lines of systemic therapy. ➤ Remarkably, ORR was 95.7% (95% CI: 89.5, 98.8). After a median follow up of 16.8 months, median DOR was not reached (95% CI: 18.04, NR). ➤ Most common nonlaboratory adverse reactions (≥20%) were cytokine release syndrome, headache, musculoskeletal pain, fatigue, constipation, and fever. #oncology #biotech #biotechnology #regulatoryaffairs #pharma #drugdevelopment #oncologytrials #oncologyresearch #cancer #oncology #regulatoryintelligence #regulatoryprecedent https://lnkd.in/eQUd_t2h

More than 30 years ago, Bispecific T-cell Engager (BiTE®) technology was developed with the goal of finding new ways to help people facing the toughest-to-treat cancers. These efforts came to fruition nearly a decade ago, when Amgen's novel immunotherapy became the first globally approved BiTE® molecule, expanding options for people with advanced B-cell lineage acute lymphoblastic leukemia (B-ALL), a patient population with historically dismal outcomes and limited treatment options. Over the past ten years, it’s been inspiring to see our T-cell engager impact relapsed or refractory and measurable residual disease (MRD)-positive B-ALL patients. Now with @FDA approval for Ph-negative B-ALL patients regardless of their MRD status, Amgen is again poised to transform possibilities for people with this aggressive blood cancer. Read more👇#MyCompany

Follicular lymphoma poses a significant challenge due to its relapsing nature and limited treatment options, particularly for patients with early progression or refractory disease. According to DelveInsight estimates, approximately 37,000 cases of follicular lymphoma were reported in the US in 2023. TQ-B3525, a novel oral PI3K α/δ inhibitor developed in China, offers a potential solution to this dilemma. By targeting both PI3K catalytic subunits α and δ, TQ-B3525 addresses drug resistance issues and minimizes toxic side effects, presenting a valuable therapeutic option. Unlock In-Depth Expert Insights and Analysis with DelveInsight Business Research LLP's Exclusive American Society of Clinical Oncology (ASCO) 2024 Reporting @ https://lnkd.in/g5-Qkrpr #FollicularLymphoma #cancer #treatmentoptions #relapse #refractorydisease #PI3Kinhibitor #TQB3525 #drugresistance #China #oncology #cancerresearch #clinicaltrials #pharmaceuticals #healthcare #patientcare

Their abstract: Despite significant advances over recent years, the treatment of T cell acute lymphoblastic leukemia (T-ALL) remains challenging. We have recently shown that a subset of T-ALL cases exhibited constitutive activation of the lymphocyte-specific protein tyrosine kinase (LCK) and were consequently responsive to treatments with LCK inhibitors and degraders such as dasatinib and dasatinib-based PROTACs. Here we report the design, synthesis and in vitro/vivo evaluation of SJ45566, a potent and orally bioavailable LCK PROTAC.

Despite significant advances over recent years, the treatment of T cell acute lymphoblastic leukemia (T-ALL) remains challenging. We have recently shown that a subset of T-ALL cases exhibited constitutive activation of the lymphocyte-specific protein tyrosine kinase (LCK) and were consequently responsive to treatments with LCK inhibitors and degraders such as dasatinib and dasatinib-based #PROTACs. Here we report the design, synthesis and in vitro/vivo evaluation of #SJ45566, a potent and orally bioavailable LCK #PROTAC. #Protac #PDC #SmallMolecule #Medchem #Medcinal #FFS #FTE #CDMO #CMC

New from Immune-Onc Therapeutics at #EHA2024! Today, we will present additional positive interim Phase 1b expansion cohort data for IO-202 in patients with chronic myelomonocytic leukemia (#CMML).  The study shows early and sustained complete remissions among CMML patients, regardless of their prognosis or mutation status. Learn more: https://lnkd.in/gZgdrvr6

Curcumin helps overcome resistance to Lenvatinib in hepatocellular cancer. The incidence of #hepatocellular carcinoma (HCC) is rising worldwide, and the therapeutic options are limited in this malignancy. #Lenvatinib is a multi‐kinase inhibitor that is often used to treat patients with HCC. However, the majority of patients develop resistance to Lenvatinib. In a recent study published in the journal Cells, our team reported that treatment with #Curcumin could help overcome Lenvatinib resistance in HCC, highlighting the potential use of this potent nutraceutical as an adjunctive treatment in this malignancy.